Aliso Viejo, CA. – January 9, 2020 – MicroVention, Inc., a U.S. based subsidiary of Terumo and a global neurovascular company announced the FDA Premarket Approval (PMA) for the FRED® (Flow Re-Direction Endoluminal Device) device for the treatment of brain aneurysms.
This Next-Generation DBS Technology Allows Physicians to Review Patient-Specific Brain Signals, Enabling More Personalized, Data-Driven Neurostimulation Treatment for Patients
Randomized Control Trial Results to be Presented at NANS Jan. 23-26 in Las Vegas; New, Proprietary Differential Target Multiplexed (DTM) Therapy Available on Medtronic Intellis Spinal Cord Stimulation Platform